Tango Therapeutics Revenue and Competitors

Boston, MA USA



Growjo Ranking



Estimated Revenue & Valuation

  • Tango Therapeutics's estimated annual revenue is currently $38M per year.(i)
  • Tango Therapeutics received $55.0M in venture funding in March 2017.
  • Tango Therapeutics's estimated revenue per employee is $193,750
  • Tango Therapeutics's total funding is $165M.

Employee Data

  • Tango Therapeutics has 196 Employees.(i)
  • Tango Therapeutics grew their employee count by 21% last year.

Tango Therapeutics's People

CFOReveal Email/Phone
SVP CommunicationsReveal Email/Phone
VP, Clinical DevelopmentReveal Email/Phone
SVP ChemistryReveal Email/Phone
SVPReveal Email/Phone
Head Computational BiologyReveal Email/Phone
VP BiochemistryReveal Email/Phone
SVP, Development OperationsReveal Email/Phone
SVP & Head Human ResourcesReveal Email/Phone
VP, Program ManagementReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

What Is Tango Therapeutics?

Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today's targeted therapies, and extend the benefit of available immuno-oncology agents. Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. What fuels each of Tango's programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity. Tango's success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Tango Therapeutics News

2022-04-20 - Wall Street Analysts Predict a 176% Upside in Tango Therapeutics, Inc. (TNGX): Here's What You Should Know

Shares of Tango Therapeutics, Inc. (TNGX) have gained 2.9% over the past four weeks to close the last trading session at $7.36,...

2022-04-17 - Tango Therapeutics, Inc. (NASDAQ:TNGX) Short Interest Update

Casdin Capital LLC acquired a new position in Tango Therapeutics during the third quarter worth $70,959,000. Southpoint Capital Advisors LP...

2022-03-30 - Tango Therapeutics Reports Fourth Quarter and Full Year 2021 ...

Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision...

2019-09-06 - Chutes & Ladders—Bausch Health's Salix loses McKenna to ...

Narayan most recently served as CBO at Tango Therapeutics. Prior to Tango, Narayan was a VP and head of transactions at Johnson ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Tango Therapeutics Funding

DateAmountRoundLead InvestorsReference
2017-03-31$55.0MAThird Rock VenturesArticle